Pipeline

Melius is developing two EcN::ttr product candidates that leverage our BioPersist™ platform. This first-in-class genetically modified microbial has several potential applications in humans and animals.

Human Product

MMB-003 is the lead drug candidate in humans to treat ulcerative colitis. Few treatments are available for mild-to-moderate colitis patients, as only the safest and most cost-effective drugs and technologies can be developed. Melius is currently preparing to submit a Clinical Trial Notification (CTN) to initiate a first-in-human clinical trial in Brisbane, Australia.

Pig Product

An EcN::ttr strain is also being tested as a feed additive for the pork industry to reduce mortality, improve feed efficiency, and increase weight gain. Melius has already tested EcN::ttr in pigs, and now aiming to receive clearance for field trials.